Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

By O. O'Connor, B. Pro, L. Pinter-Brown, N. Bartlett, L. Popplewell, B. Coiffier, M. Lechowicz, K. Savage, A. Shustov, C. Gisselbrecht and 10 more. Journal of Clinical Oncology, 2011

609 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/ef108cf955bf0e74d93943a4b88c8af82307b9ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Sievers
2. R. Advani
3. P. Brice
4. J. Rosenblatt
5. T. Illidge
6. J. Connors
7. N. Bartlett
8. D. Kennedy

Citations in the corpus

• Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. (2012, background): “ALCL, six of 17 patients achieved an objective response with pralatrexate.(18) With romidepsin, the proportions of patients who achieved B A”